The program is presented as a tool that allows you to analyze multigenomic and clinical data efficiently.
Health researchers at Rutgers Health in the US have taken a significant step in disease prediction by developing the revolutionary computer program IntelliGenes. This pioneering software, which combines artificial intelligence (AI) and machine learning, focuses on measuring the relevance of specific genomic biomarkers to predict diseases at the individual level.
In a study published in Bioinformaticsdetails how IntelliGenes It is presented as an accessible tool for a wide range of users. This program allows you to analyze multigenomic and clinical data efficiently, thereby overcoming the barrier of complexity for those who are not experts in the field.
An inclusive approach to genomic research
The study’s lead author and professor at Rutgers’ Institute for Health, Health Policy and Aging (IFH) Research, Zeeshan Ahmed, highlights the lack of AI or machine learning tools to investigate the entire human genome, especially for non-experts. IntelliGenes It has been designed by Ahmed and his team to be accessible to anyone, including students and those without extensive knowledge of bioinformatics techniques or access to high-performance computers.
This innovative software combines conventional statistical methods with cutting-edge machine learning algorithms. The result: personalized predictions for patients and a visual representation of biomarkers significant in disease prediction.
Significant discoveries in cardiovascular research
In another study, published in Scientific Reportsthe researchers applied IntelliGenes to discover new biomarkers and predict cardiovascular diseases with remarkable accuracy.
“The convergence of data sets and the amazing advances in artificial intelligence and machine learning hold enormous potential,” said Ahmed, who is also an associate professor of Medicine at the Robert Wood Johnson Medical School in the US. “IntelliGenes “It can support personalized early detection of common and rare diseases in individuals, as well as open avenues for broader research that ultimately leads to new interventions and treatments,” added Ahmed.
Validation through ‘Amarel’
Additionally, the researchers validated the software by using Yellowhe cluster of high-performance computing managed by the Rutgers Office of Advanced Research Computing. This office provides a research computing and data environment to Rutgers researchers involved in complex computing and data-intensive projects.